Magnetic manipulation device for the optimization of cell processing conditions

Journal of Bioscience and Bioengineering
Hiroshi ItoHiroyuki Honda

Abstract

Variability in human cell phenotypes make it's advancements in optimized cell processing necessary for personalized cell therapy. Here we propose a strategy of palm-top sized device to assist physically manipulating cells for optimizing cell preparations. For the design of such a device, we combined two conventional approaches: multi-well plate formatting and magnetic cell handling using magnetite cationic liposomes (MCLs). From our previous works, we showed the labeling applications of MCL on adhesive cells for various tissue engineering approaches. To feasibly transfer cells in multi-well plate, we here evaluated the magnetic response of MCL-labeled suspension type cells. The cell handling performance of Jurkat cells proved to be faster and more robust compared to MACS (Magnetic Cell Sorting) bead methods. To further confirm our strategy, prototype palm-top sized device "magnetic manipulation device (MMD)" was designed. In the device, the actual cell transportation efficacy of Jurkat cells was satisfying. Moreover, as a model of the most distributed clinical cell processing, primary peripheral blood mononuclear cells (PBMCs) from different volunteers were evaluated. By MMD, individual PBMCs indicated to have optimum Interleuk...Continue Reading

References

Oct 12, 1984·Journal of Immunological Methods·C S Owen, N L Sykes
Nov 1, 1996·Japanese Journal of Cancer Research : Gann·M ShinkaiT Kobayashi
May 18, 2001·Nature·F R Appelbaum
Mar 11, 2004·The International Journal of Biochemistry & Cell Biology·Frank P Barry, J Mary Murphy
Mar 17, 2004·Nature Biotechnology·Jong Wook HongStephen R Quake
Jun 9, 2004·The Journal of Experimental Medicine·Qizhi TangJeffrey A Bluestone
Dec 8, 2004·Biotechnology and Bioengineering·Paul J HungLuke P Lee
Oct 21, 2005·Proceedings of the National Academy of Sciences of the United States of America·Xiaoyuan HuHyongsok T Soh
Dec 24, 2005·Lab on a Chip·Alexandra B FuchsNicolo Manaresi
Jul 26, 2006·Biotechnology and Bioengineering·Kazunori ShimizuHiroyuki Honda
Jan 12, 2007·Biotechnology and Bioengineering·Kosuke InoHiroyuki Honda
Feb 7, 2007·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Kazunori ShimizuHiroyuki Honda
Jun 6, 2007·The Journal of Clinical Investigation·Carl H June
Jan 22, 2008·Nature Medicine·Radbod DarabiRita C R Perlingeiro
Apr 1, 2008·Nature Biotechnology·Johannes L ZakrzewskiMarcel R M van den Brink
Jul 16, 2008·Journal of Chromatography. a·Michael KirschbaumClaus Duschl

❮ Previous
Next ❯

Citations

Dec 24, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jia-Kun XuMi Sun
Jun 15, 2010·Journal of Bioscience and Bioengineering·Hiroshi ItoHiroyuki Honda
May 13, 2015·Bioprocess and Biosystems Engineering·Shuhei YamamotoHiroyuki Honda
Feb 10, 2012·Chemical Society Reviews·Yue PanBing Xu
Dec 28, 2017·Advanced Healthcare Materials·Vanessa Fernandes CardosoSenentxu Lanceros-Mendez
Jul 2, 2021·Electrophoresis·Hao ChengMing Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.